华兰疫苗 reported revenue of ¥0.04B for the period ended 2026-06-30, -26.0% year on year. Net income was ¥0.04B, a 82.1% net margin on a 47.8% gross margin. The largest revenue line is 狂犬疫苗 at 89% of the total. Free cash flow for the period was ¥0.06B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.04B | -26.0% |
| Gross profit | ¥0.02B | — |
| Operating income | ¥0.04B | — |
| Net income | ¥0.04B | +75.2% |
| Gross margin | 47.8% | Net margin 82.1% |
| Revenue Q/Q | -34.2% | — |
| Segment | Revenue | Share |
|---|---|---|
| 狂犬疫苗 | ¥0.04B | 89.5% |
| 流感疫苗 | ¥0.00B | 5.4% |
| 其他(补充) | ¥0.00B | 4.0% |
| 其他主营业务 | ¥0.00B | 1.1% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.02B | 52.2% |
| R&D | ¥0.04B | 98.6% |
| SG&A | ¥0.04B | 100.6% |
| Tax & other | ¥-0.00B | -2.3% |
| Item | Amount |
|---|---|
| Total assets | ¥6.28B |
| Total liabilities | ¥1.01B |
| Shareholders' equity | ¥5.26B |
| Equity / assets | 83.8% |
| Operating cash flow | ¥0.06B |
| Capital expenditure | ¥0.00B |
| Free cash flow | ¥0.06B |
| Cash conversion (OCF / net income) | 456% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
中亦科技 ・ 联合化学 ・ 金杨精密 ・ 亨迪药业 ・ 联盛化学 ・ 观想科技 ・ 中汽股份 ・ 万凯新材 ・ 铜冠铜箔 ・ 华是科技 ・ 腾远钴业 ・ 亚香股份
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies